Esteve Quimica S.a.

Miquel A Pericas Brondo

Llorenç Rafecas Jané

Juan José Artús Surroca

Lourdes Garriga Sanahuja

Lluís Solà Carandell

Llorenç Rafecas Jane

Juan José Artus Surroca

A process for obtaining the pharmaceutical active ingredient, levetiracetam, by means of deaminomethylation of a sufficiently pure enantiomer intermediate (S)-(II), or by means of deaminomethylation of an addition salt thereof with an acid, wherein Rand Rare either the same or different (C-C)-alkyl radicals, or else Rand Rtogether with the nitrogen atom to which they are bonded form a radical selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 1-piperazinyl and 1-[4-(C-C)-alkylpiperazinyl]. The invention also comprises preparing the sufficiently pure enantiomer intermediate (S)-(II) by treating the corresponding chemically new racemic intermediate (II) with an amine resolving agent, followed by selective crystallisation of a diastereoisomeric salt thereof. It is useful for obtaining levetiracetam on an industrial scale and involves neither hydrogenation nor chromatography 

Growing community of inventors

Esplugues del Llobregat, Spain

Miquel A Pericas Brondo